Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose intravaginal oxybutynin MedRing pharmacokinetics study in healthy women
NL-OMON51105Active, not recruiting
- Sponsor
- LiGalli
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxybutynin in overactive bladder (OAB), urge incontinence and hot flash, sponsored by LiGalli. Primary endpoints: AUCinf of oxybutynin and N-desethyloxybutynin, AUClast of oxybutynin and N-desethyloxybutynin and 9 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)urge incontinencehot flash
Beyond the preview
Go deeper on NL-OMON51105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51105.